WARSAW, Ind., Nov. 14, 2025 /PRNewswire/ -- Zimmer Biomet Holdings, Inc. (NYSE and SIX: ZBH), a global medical technology leader, today announced U.S. Food and Drug Administration (FDA) 510(k) ...
Add Yahoo as a preferred source to see more of our stories on Google. The system offers a simplified user interface Zimmer Biomet has received 510(k) clearance from the US Food and Drug Administration ...
Zimmer Biomet is focusing on growth acceleration after spinning off divisions and refocusing on high-growth areas in the medical device market. The company's growth target is supported by investments ...
Zimmer Biomet's ZBH strategic focus on ROSA Robotic Platform and stabilizing market trends bolster investors’ confidence in this stock. The stock carries a Zacks Rank #2 (Buy) at present. ZBH ...
Zimmer Biomet’s ZBH focus on emerging markets and stabilizing market trends have bolstered our confidence in this stock. Yet, factors like macroeconomic uncertainties, pricing pressure and unfavorable ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results